Health Care·Biotechnology·$11.8B
Madrigal Pharmaceuticals (MDGL) is a biotechnology company focused on developing innovative therapies for liver diseases, particularly non-alcoholic steatohepatitis (NASH). With a market cap of $12 billion, its advancements in this area could significantly impact patient care and the healthcare market.
EPS
Earnings per share (EPS) is a critical measure of profitability, and this quarter's consensus indicates continued losses, which could influence investor sentiment.
Revenue
Revenue figures will provide insight into the company's sales performance and market acceptance of its products, especially as it approaches potential commercialization.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
-936.84%
Avg Stock Reaction
+2.36%
In Q4 2025, Madrigal reported a significant EPS miss, leading to a notable drop in stock price. Revenue details were not disclosed, leaving investors uncertain about the company's financial health.
Management Promises & Guidance
Analysts expect Madrigal to report continued losses but are looking for any signs of revenue growth that could indicate a path to profitability. The upcoming earnings report is crucial for assessing the company's future prospects.
Bull Case
If Madrigal beats EPS estimates and shows strong revenue growth, it could signal robust demand for its therapies, leading to a positive market reaction.
Bear Case
A significant miss on EPS or revenue could raise concerns about the company's viability and lead to further stock declines.
EPS
-$4.14Earnings per share (EPS) is a critical measure of profitability, and this quarter's consensus indicates continued losses, which could influence investor sentiment.
Revenue
$302MRevenue figures will provide insight into the company's sales performance and market acceptance of its products, especially as it approaches potential commercialization.
The print will turn on these two things.
Q1
Will the EPS come in better than the consensus estimate of -$4.14?
A better-than-expected EPS could indicate improved operational efficiency or cost management, positively impacting investor confidence.
Q2
What is the revenue outlook for this quarter, especially in light of the $302M consensus?
Revenue performance is critical for assessing the company's market traction and potential for future growth, especially as it seeks to commercialize its products.
Why consensus could be wrong
The Street may be underestimating Madrigal's potential for revenue growth due to its innovative pipeline, which could lead to better-than-expected sales.
Supporting Evidence
Recent clinical trial results have shown promising efficacy, which may not be fully reflected in current revenue estimates.
The company's focus on NASH could position it favorably in a growing market, contrary to bearish sentiment.
Management's commitment to improving investor communication could enhance market confidence.
Key Risk
If the revenue comes in above $308M, it could challenge the current bearish outlook.
Pre-commit to what would confirm each case.
The market is debating whether Madrigal can turn around its financial performance and demonstrate growth potential amid ongoing losses.
Bull Confirmed If
Reporting an EPS of -$3.79 or better alongside revenue exceeding $308M would confirm strong market demand.
Bear Confirmed If
An EPS worse than -$4.48 and revenue below $295M would indicate ongoing challenges in the business.
Implied Move
±4.2%
The options market is not currently available, but the implied move suggests some volatility is expected around the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Madrigal beats expectations, history suggests a potential average stock move of +5.93%, confirming a positive outlook for the company.
In-Line / Cautious
If results are in line with expectations, the stock may react cautiously, reflecting uncertainty about future growth.
Miss
A significant miss could lead to a decline of around -3.59%, reinforcing bearish sentiment about the company's prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026